TABLE 1.
Examples on potential RNA-based COVID-19 vaccine candidates currently undergoing clinical trials.
| Name of the vaccine | RNA type | Sponsor(s) | No. of doses | Dosing interval (days) | Clinical trial phase and identifier |
|---|---|---|---|---|---|
| mRNA-1273 | LNP-encapsulated mRNA | Moderna inc. and NIAID | 2 | 0, 28 | Phase III NCT04470427 |
| Phase II NCT04405076 | |||||
| Phase I NCT04283461 | |||||
| BNT162 (1a, b1, b2, c1) | LNP-encapsulated nucleoside modified mRNA, uridine containing mRNA, and self-amplifying mRNA | BioNTech, fosun pharma, and pfizer | 2 | 0, 28 | Phase III NCT04368728 |
| Phase II 2020-001038-36, ChiCTR2000034825, NCT04537949, NCT04588480 | |||||
| Phase I NCT04368728 | |||||
| CVnCoV | mRNA | CureVac | 2 | 0, 28 | Phase II NCT04515147 |
| Phase I NCT04449276 | |||||
| LNP-nCoVsaRNA | Self-amplifying mRNA | Imperial college london | 2 | — | Phase I ISRCTN17072692 |
| ARCT-021 | Self-replicating RNA | Arcturus therapeutics, inc. and Duke-NUS | — | — | Phase I/II NCT04480957 |
| Unnamed | mRNA | PLA, walvax biotechnology, and abogen biosciences | 2 | 0, 14 and/or 0, 28 | Phase I ChiCTR2000034112 ChiCTR2000039212 |
| ChulaCov19 | mRNA | Chulalongkorn university | 2 | 0, 28 | Phase I NCT04566276 |